Yang Y, Yang JJ, Tao H and Jin WS. YKL-40 and EGFR is a good biomarker for predicting nodal metastasis in anal carcinoma. Colorectal Dis 2014; 16: 69.Yang Y, Yang JJ, Tao H, Jin WS: YKL-40 and EGFR is a good biomarker for predicting nodal metastasis in anal carcinoma. Colorectal...
The above results indicated that C D200+ CAFs may play a major role in the therapeutic application of EGFR-TKIs [255]. In pancreatic cancer, CD200 is positively expressed in CAFs and negatively expressed in cancer cells, but no clear correlation is seen with either progression-free ...
Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma. Br J Cancer. 2003; 89 :1266–1269. doi: 10.1038/sj.bjc.6601241. [ Cross Ref ]allio JP,Hirvikoski P,Helin H. Membranous location of EGFR immunostaining is associated with good prognosis in ...
Consequently, the induced M2-like macrophages enhance the resistance of H1975 cells to EGFR-tyrosine kinase inhibitors (TKIs)93. Exosomal SNHG7 downregulates PTEN by recruiting cullin 4 A (CUL4A), subsequently stimulating the PI3K/Akt pathway. Based on this, exosomal SNHG7 induces M2-like ...
[124]. AURKA not only stabilizes SDCBP by phosphorylating it at the S131 and T200 sites, but the phosphorylation of these sites also allows SDCBP to bind EGFR and prevent its internalization (Table1). Sustained EGFR signaling activates the PI3K-AKT pathways to promote highly oncogenic signaling ...
Pharma has a great opportunity ahead of it when it comes to conducting representative clinical trials. The industry’s application of mRNA techniques during the pandemic led to the fastest vaccine development in history. The processes used are now seeing
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–89. https://doi.org/10.1016/S1470-2045(16)30033-X. Clinical Trial, Phase II...
Another study revealed that CLDN18 coupled with modulation of epidermal growth factor receptor (EGFR) / extracellular signal-regulated kinase (ERK) signaling contributes to the malignant potential of bile duct cancer [48]. Thus, CLDN18.2, as a unique molecular biomarker, may be used for targeted...
In breast cancer theCXCR4mRNA promotes metastasis not only through its protein, the CXCR4 chemokine receptor, but also through theCXCR43′UTR that sponges the tumor-suppressive miR-146a, thus leading to the upregulation of TRAF6 and EGFR, two oncoproteins that activate the NF-κB pathway.148 ...
As expected, KRAS knock-down led to a significant decrease in the activity of the EGFR and MAP kinase signaling. The activity of these pathways was not strongly affected by UHRF1 knock-down in either cell line, suggesting that they are not regulated by UHRF1. To determine whether UHRF1 ...